Merus (NASDAQ:MRUS) Now Covered by Piper Sandler

Piper Sandler initiated coverage on shares of Merus (NASDAQ:MRUS) in a report released on Thursday morning, MarketBeat.com reports. The firm issued an overweight rating and a $84.00 target price on the biotechnology company’s stock.

MRUS has been the subject of several other reports. Needham & Company LLC reissued a “buy” rating and issued a $85.00 price target on shares of Merus in a research report on Monday, December 9th. Wells Fargo & Company started coverage on shares of Merus in a report on Friday, February 7th. They issued an “overweight” rating and a $91.00 target price for the company. The Goldman Sachs Group started coverage on shares of Merus in a report on Thursday, November 21st. They issued a “buy” rating and a $73.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $85.00 price objective on shares of Merus in a research note on Monday, December 2nd. Finally, Guggenheim reissued a “buy” rating on shares of Merus in a research report on Wednesday. One research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Merus presently has an average rating of “Buy” and an average price target of $85.92.

Merus Stock Up 0.1 %

Shares of NASDAQ:MRUS opened at $40.30 on Thursday. The firm has a 50 day moving average of $41.71 and a 200 day moving average of $47.37. The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of -10.20 and a beta of 1.11. Merus has a 52 week low of $37.77 and a 52 week high of $61.61.

Institutional Investors Weigh In On Merus

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its stake in Merus by 73.6% during the 3rd quarter. Wellington Management Group LLP now owns 2,887,514 shares of the biotechnology company’s stock worth $144,260,000 after purchasing an additional 1,224,573 shares during the last quarter. FMR LLC boosted its position in Merus by 10.4% during the third quarter. FMR LLC now owns 6,873,926 shares of the biotechnology company’s stock worth $343,421,000 after acquiring an additional 648,994 shares during the last quarter. Westfield Capital Management Co. LP acquired a new position in Merus during the third quarter worth about $30,399,000. Lord Abbett & CO. LLC grew its stake in Merus by 83.0% during the 3rd quarter. Lord Abbett & CO. LLC now owns 723,988 shares of the biotechnology company’s stock valued at $36,171,000 after acquiring an additional 328,316 shares in the last quarter. Finally, Affinity Asset Advisors LLC raised its holdings in Merus by 140.7% in the 4th quarter. Affinity Asset Advisors LLC now owns 389,241 shares of the biotechnology company’s stock valued at $16,368,000 after acquiring an additional 227,500 shares during the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.